About Us
Our Science
Pipeline
Development Programs
Investors & Collaborators
News
Medical Information
- Publications
- Expanded Access
Contact

Privacy Policy
Disclaimer

✕

Medical Information

Publications
Expanded Access

© 2017 - 2025 Nacuity Pharmaceuticals, Inc. All Rights Reserved

Privacy Policy
Disclaimer

conner_200

Halden Conner

Chairman, CEO, Co-Founder

Former Alcon Laboratories Board Member
Former Wilmer Advisory Council Member
Co-founder, Protom International

mwall_2

G. Michael Wall, PhD

SVP, CSO

22 years at Alcon Laboratories, directing all phases of ophthalmic, otic, nasal drug development, numerous products
56 patents, 120 pubs & abstracts, 2 books, 9 suppls, 3 chapters
Directed more than 40 clinical trials
PhD, Medicinal Chemistry, University of Mississippi School of Pharmacy
Harvard Business School AMP

kern

Jami R. Kern, MBA, PhD

SVP, Chief Clinical Officer

Extensive experience, pharmaceutical and medical device industries
Led clinical development and medical affairs at Alcon Research for 15 years
MBA, Neeley School of Business at TCU
Ph.D. in Biomedical Science, Molecular Biology & Biochemistry, UNT Health Science Center

anderson_200

Lee Anderson, MD

Ophthalmologist in Residence

Over 20 years in practice specializing in Ophthalmology and Retinal Disease
MD, University of Texas Medical Branch
Fellowship Bascom Palmer Eye Institute

lieser_200

Charles Lieser, JD. CPA

CFO

Owner, Weaver, LLP, 32 years
40 plus years experience public accounting
Principal and advisor to numerous companies

cagle_200

Gerald D. Cagle, PhD

Former Global Head R&D, Chief Scientific Officer, & VP Regulatory Affairs, Alcon Laboratories
>20 issued patents and numerous peer reviewed scientific articles
Director, Aerie, Clearside Biomedical, GrayBug Drug Delivery and FFB-CRI

Emmett-Cunningham-Headshot200x200

Emmett T. Cunningham, Jr.
MD, PhD, MPH

Senior Partner, HealthQuest Capital Management
Co-Founder and Executive Chairman, Eyconis, Inc.
Former Senior Managing Director, Blackstone, Inc.
Co-Founder and former Chairman, Ophthalmology Innovation Summit (OIS)

russell_kelley-05_crop_bod

Russell Kelley, PhD, MBA

Managing Director, RD Fund
Former Scientist, Director and Head of preclinical, Tengion
Board Director, Opus Genetics and SparingVision
Board Observer, Atsena Therapeutics, Perceive Bio, Amber Bio and Perceive Pharma

steele_200

Robin Steele, JD, LLM

Director, Daré Bioscience, Inc. and Alveo Technologies, Inc.
Former Senior Vice President, General Counsel, and Secretary of InterMune, Inc.
Former Vice President of Legal Affairs for North America, Elan Pharmaceuticals, Inc.

wohlberg_200

David Wohlberg, Esq.

Vice-Chairman, Co-Founder, Nacuity Pharmaceuticals, Inc.
Former President, ImmunoCellular Therapeutics, Inc.
Of Counsel, TroyGould PC

yerxa_200

Benjamin R. Yerxa, PhD

President, Opus Genetics
Former CEO, FFB and RD Fund
Former President and Chief Scientific Officer, Envisia Therapeutics
Former Chief Scientific Officer, Liquidia Technologies
Former Vice President for Research and Development, Clearside Biomedical

birch_200

David Birch, PhD

Scientific Director, Retina Foundation of the Southwest
Director, Rose-Silverthorne Retinal Degenerations Laboratory
PhD, University of California, Santa Barbara

holekamp

Nancy Holekamp, MD

Principal Global Medical Science Lead, Roche Pharmaceuticals
Professor of Clinical Ophthalmology Washington U. School of Medicine
Director of Retina Services, Pepose Vision Institute
MD, Johns Hopkins University School of Medicine

Richard Lindstrom picture

Richard L. Lindstrom, MD

Founder and Attending surgeon, Minnesota Eye Consultants
Senior Lecturer and Trustee, University Foundation at the University of Minnesota
Executive Committee and Board of Directors, American Society of Cataract and Refractive Surgery
MD, University of Minnesota

pennesi_200

Mark Pennesi, MD, PhD

Director of Ophthalmic Genetics, Retinal Foundation of the Southwest
Prevent Blindness and FFB development awards for transitional research in RP
MD/PhD, Baylor College of Medicine

stout_200

Tim Stout, MD, PhD, MBA

Director, Cullen Eye Institute, Baylor College of Medicine
Chair, Department of Ophthalmology, Baylor College of Medicine
MD/PhD, Baylor College of Medicine
MBA University of Oregon

dorfman_200

Scott Dorfman

Co-Founder, CEO and Chairman, Odylia Therapeutics
Founder, former Chairman and CEO of Innotrac Corporation
Board Member: Dropoff, DriverReach, Complemar, Fulcrum Equity Partners, BioNeex, Usher 2020 Foundation
BBA, University of Georgia

feller_200

Daniel Feller

Owner and CEO, Talisman Healthcare
COO, GEM42S Ltd.
Board Member: Genetic Cures Australia
B.A. (Hons.) in French with International Relations, University of Warwick

carol_200x200

Carol Lakkis, BScOptom, PhD, PGCertOcTher

Director/R&D Technical Director
Nacuity Pharmaceuticals, Pty, Ltd

Director, iBiomedical Consulting
Honorary Enterprise Professor, The University of Melbourne
Previously, Johnson & Johnson Vision Care, Inc.
PhD, Ocular Microbiology and BSc, Optometry, University of Melbourne

marvin_garrett200x200

Marvin J. Garrett

Regulatory Consultant, Regulatory Affairs strategy and submissions, FDA relations, Quality, Clinical and Compliance
Key team member 4 successful start-ups and Sr. executive roles (VP, CEO & GM) with Allergan, J&J, CooperVision, ISTA, Aerie, Bausch and Alcon
Past Chair and President of Regulatory Affairs Professional Society
Four decades of global experience in pharmaceuticals, biologics and medical devices, responsible for 60+ product approvals
Education: MA business Management Redlands, CA; BS Microbiology CSULB, CA; Regulatory Affairs Certification

wiley_chambers200x200

Wiley A. Chambers, MD

Ophthalmic Pharmaceutical Consultant

Clinical Professor, Ophthalmology & Adjunct Asst Prof Computer Medicine, The George Washington University, Washington, D.C.
Formerly, Director, Division of Ophthalmology, CDER, U.S. FDA, 36 years
American Academy of Ophthalmology, Life Achievement Honor Award
Lighthouse Guild’s Bressler Prize
Prevention of Blindness Society of Metropolitan Washington’s Professional Services Award
Education: Undergraduate (BA), Colgate University; MD & Ophthalmology Residency, The George Washington University School of Medicine and Health Sciences, Washington, D.C.

onkar_singh200x200

Onkar Singh, PhD, MBA

Formulations Consultant, President, OS Pharma Consulting, LLC

VP, Alentia Therapeutics (solid oral dosage-neurodegeneration)
Previously: Director, Product Development, Henry M. Jackson Foundation for the Advancement of Military Medicine (HIV vaccine); Director, Pharm Dev at CONRAD (EVMS) (tablet, implants, patch, nanoparticles); Director, Insys Therapeutics (oral solution, sublingual, nasal sprays); Sr CMC Team Leader, 20-years at Alcon Labs/ Novartis (sterile otic, ophthalmic, nasal drug products)
Education: BPharm, Pharmacy, & MPharm, Pharmaceutics, Indian Institute of Technology (IIT), Banaras Hindu University; PhD Pharmaceutics, Univ. of Illinois at Chicago; MBA, Univ. of Texas at Arlington